Conference Summaries: Day Two<BR> Monday, July 9, 2001

The Body Covers: The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment

Conference Summaries: Day Two
Monday, July 9, 2001

Clinical Trials
Viral Reservoirs
- Monitoring Intracellular HIV-1 Replication in Blood and Lymphoid Tissue in Antiretroviral Naive Subjects Receiving Amprenavir (APV), Abacavir (ABC), and 3TC (COLA3003 Study) (Abstract 25)
  Coverage by Alvan Fisher, M.D.
Treatment Strategies
- Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (Abstract 30)
  Coverage by Pablo Tebas, M.D.
- Effects of Prolonged Discontinuation of Successful Antiretroviral Therapy (Abstract 31)
  Coverage by Pablo Tebas, M.D.
Liver Diseases and HIV
- Pegylated Interferon Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients (Abstract 42)
  Coverage by Douglas T. Dieterich, M.D.
Update On Resistance
- New Antiretrovirals Host Immunology, Pathogenesis and Dynamics Mechanisms of HIV-Drug Resistance Drug Resistance, Exposure and Treatment Response Genotype/Phenotype Relationship, Modelling and Algorithms (Abstracts 50, 51, 52)
  Coverage by Calvin J. Cohen, M.D., M.S.
Pharmacological Issues in ARV Therapy
- Therapeutic Drug Monitoring: A Must for Clinical Practice? (Abstract 54)
  Coverage by Andrew T. Pavia, M.D.
Antiretroviral Therapy I
- Abacavir (ABC), Lamivudine (3TC) and Amprenavir (APV) +/- Ritonavir (RTV) Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (Poster 216)
  Coverage by Pablo Tebas, M.D.
- The PI-Sparing Compact Quad Regimen of Combivir (COM)/Abacavir (ABC)/Efavirenz (EFV) is Potent and Well-Tolerated in Antiretroviral Therapy (ART) Naive Subjects with High Viral Loads: 24-Wk Data (Poster 221)
  Coverage by Andrew T. Pavia, M.D.
New Antiviral Drugs
- Evaluation of the Anti-HIV-1 Potency of Several Nucleoside RT Inhibitors in PBL, Macrophages, and MT4 Cells, In Vitro (Poster 248)
  Coverage by Brian A. Boyle, M.D., J.D.
Cost Benefit and Outcomes of HAART
Pharmacology

Previous Day's Sessions | Next Day's Sessions

Return to The Body's coverage of
The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment.

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.